Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 12/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3883399 | 0.92 | PTK2 (0.53) | PTK2MAPK13MAPK14CYP2D6CYP2C9 | |
| SCHEMBL3877098 | 0.91 | PTK2 (0.58) | PTK2MAPK13MAPK14CYP2D6CYP2C9 | |
| SCHEMBL3882665 | 0.91 | MAPK14 (0.54) | PTK2MAPK13MAPK14CYP2D6CYP2C9 | |
| SCHEMBL3882493 | 0.91 | MAPK14 (0.54) | PTK2MAPK13MAPK14CYP2D6CYP2C9 | |
| SCHEMBL3880070 | 0.91 | MAPK14 (0.55) | PTK2MAPK13MAPK14CYP2D6CYP2C9 | |
| SCHEMBL3886346 | 0.90 | MAPK14 (0.54) | PTK2MAPK13MAPK14CYP2D6CYP2C9 | |
| SCHEMBL3876473 | 0.89 | MAPK14 (0.52) | PTK2MAPK13MAPK14CYP2D6CYP2C9 | |
| SCHEMBL3887898 | 0.89 | MAPK14 (0.52) | PTK2MAPK13MAPK14CYP2D6CYP2C9 | |
| SCHEMBL5826342 | 0.87 | MAPK14 (0.53) | PTK2MAPK13MAPK14CYP2D6CYP2C9 | |
| SCHEMBL3876218 | 0.87 | MAPK14 (0.52) | PTK2MAPK13MAPK14CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | PTK2 1093/4885MAPK13 44/4885MAPK14 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.